



_ Pati	EASE CHEC	thorization on	file author	izing the release of the	patien	t's identification and	insurar	nce infor	mation to	Sanofi	US, and thei	r agents
□ and representatives for Benefit Verification (BV)  Reimbursement Connection (BV)  □ BV only (Complete sections 1-3) (No signature □ BV and Patient Assistance (If no coverage is for and patient signature required) (Complete sections 1-3)				atures required) s found, prescriber	☐ Patient Assistance Connection (made possible by Sanofi Cares North America). No cost medication program, prescriber and patient signature required (Complete sections 1-3, 5)			nes_ per	Resource Connection Additional patient resources, patient signature required (Complete sections 1-5)			
1. P	ATIENT INF	ORMATIC	ON									
				MI:Last N	lame:				Geno	der:	]м □ғ	
									Zip Code:			
Phone #:												
Primar	y Insurance:				5	Secondary Insurance	e:					
Policy	#:				F	Policy #:						
	Holder Name:					Policy Holder Name:						
Date of						Date of Birth:						
	nce Phone #:					nsurance Phone #:  Broup #:						
Group	#.					510up #.						
2. TREATMENT AND PRESCRIBING INFORMATION (see instructions on page 3 for available products)  For Lantus® (insulin glargine injection) 100 Units/mL and/or Apidra® (insulin glargine [rDNA origin] injection), indicate vials or pens. All other medications used for the treatment of diabetes available in pen only. An example is in the top line of the table below:										other		
Drug:	Lantus Solost	ar 3 ml	ICD/Dx:	Enter ICD-10 Code		30 u BID		90 day		Refills:	3	
Drug:			ICD/Dx:		Rx:		Qty:			Refills:		
Drug:			ICD/Dx:		Rx:		Qty:			Refills:		
Drug:			ICD/Dx:		Rx:		Qty:			Refills:		
3. P	RESCRIBE	R INFORM	ATION									
Prescrib	er Name:			Prescriber Typ	oe:		S	State wh	ere Licer	nsed:		
					Tax ID #:							
Facility N	•			Facility Type: ☐ F								
-	·					Sta	-		-		-	
•				g prescriber's office o								ty.
Primary	Contact Name	:				Title/Role:						
Primary	Phone #:		Pr	imary Fax #:		Primary	/ Emai	l:				
this patie required America coverage Connecti receive a hospital a resold no	ent and that I an written authorize and their agents to assess, if on program and any benefit from address. My sigr	n authorized un authorized un tion for the rele and represent applicable, pair related services anoficor their lature certifies de, trade or bair	Inder State lease of my ntatives. I u itient's eligi ses. I under agents or i that any pr	mplete, and accurate to to law to prescribe and discontinuous patient's personal identification in the properties of the prescription in the presentatives for prescription products receil not be returned for cre	spense ification mation the p o oblig ribing of ived from	e the requested medion, medical and insurant provided is for the solution to prescribe and Sanofi product. The tom this Program will be	cation. Ince info ole use ogram a y Sano facility e used	I certify to crmation of the F and to o fi produc address for the a	that I have to Sanofi Program to therwise t and that noted abo bove nam	e obtain US and o verify adminis t I have ove in S ned patie	ed from my p for Sanofi Ca my patient's i ter the Sano not received ection 3 is my ent only and w	patient all res North insurance fi Patient nor will I v office or vill not be
SIGN H		Prescriber Sign	ature (requ	ired – no stamps)		Printed N	Name				Date	

4. RESOURCE CONNECTION							
Does the patient wish to have the program contact them to help identify resources provided by other organizations?							
☐ Yes (Patient signature required below) ☐ No							
If yes, please mark which resources the patient may be interested in if available:							
☐ Clinical Support Services ☐ Transportation ☐ Patient Advocacy Support ☐ Nutritional Supplements (groceries, food banks, etc.)							
☐ Health Supplies/Cosmetic Aids (wigs, scarves, etc.) ☐ Home Care Services (shelter, utilities, etc.) ☐ Other:							
5. PATIENT ASSISTANCE CONNECTION (certification and authorization to disclose information)							
Total # of people in the household: □1 □2 □3 □4 □5 □ Other:Annual Household Income: \$							
<b>Income Verification:</b> Sanofi Patient Connection and its authorized third party agents will use my date of birth or social security number and/or additional demographic information as needed to access my credit information and information derived from public and other sources to estimate my income in conjunction with the eligibility determination process. As a soft credit inquiry, this option will not impact my credit score. Sanofi Patient Connection and its authorized third party agents reserve the right to ask for additional documents and information at any time.							
Patient Name (Please Print): I, , state that the information and documents provided in connection with this application are complete and accurate. I agree to immediately inform a Program representative and my Doctor/ Healthcare Provider if my income or insurance status changes during the course of my participation in this Program. I understand that my information will be used by the Program sponsor, Sanofi US, its affiliated companies (i.e. Sanofi Pasteur U.S. and Genzyme, a Sanofi Company), Sanofi Cares North America, and authorized third party agents involved in administration of this Program, (collectively "Program Sponsor"), for purposes of determining my participation in, and administering, the Program, which may include contacting me as well as my Doctor/Healthcare Provider, office/hospital staff, insurer (public/private) or others. I understand a representative from Sanofi may contact me for follow-up on any adverse event I may report regarding a Sanofi product. I authorize and consent to release of identifiable information about me including medical, financial and insurance records and information as required for participation in the Program. My authorization includes release of information relating to treatment for substance abuse, psychiatric and/or medical conditions, and HIV test results or diagnosis, if required. I understand that identifiable information about me will be kept confidential and will not be further used or disclosed except to administer the Program, or as required by law. I understand that information I authorize to be disclosed may be re-disclosed and is no longer protected by Federal privacy regulations. I agree that this authorization is voluntary and that I may refuse to sign this authorization. Refusal to sign will not affect throughout my participation in the Program, including subsequent reapplication as required. I may withdraw this authorization at any time by written notification to my Doctor/Healthcare Provider; however withdrawal of authorization will terminate my partici							
status of my application request.							
Representative/Organization: Relationship: Phone #:							
Patient Signature Printed Name Date							
APPLICATION CHECKLIST (application will be delayed if all information is not received)							
■ HIPAA consent checked or provider signature included							
The following must be completed as needed: Dosage, Diagnosis Code, State License Number, Insurance Details							
☐ Signatures of prescriber and patient (required for Patient Assistance Connection)							

Signature of patient (required for Resource Connection)

## PRODUCT SELECTION (please enter desired product in Section 2 for all services)

- Adacel<sup>®</sup> (tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed)
- ADMELOG<sup>®</sup> (insulin lispro injection) 100 Units/mL
- · Adlyxin® (lixisenatide) injection
- Apidra<sup>®</sup> (insulin glulisine [rDNA origin] injection)
- Clolar<sup>®</sup> (clofarabine) Injection
- Elitek® (rasburicase)\*
- Imogam<sup>®</sup> Rabies-HT Immune Globulin, [Human] USP, Heat Treated
- Imovax<sup>®</sup> Rabies Vaccine [Human Diploid Cell]
- Jevtana<sup>®</sup> (cabazitaxel) Injection\*
- Lantus<sup>®</sup> (insulin glargine injection) 100 Units/mL
- Lovenox<sup>®</sup> (enoxaparin sodium injection)\*

- Menactra<sup>®</sup> Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diptheria Toxoid Conjugate Vaccine
- Mozobil<sup>®</sup> (plerixafor injection)
- Multaq<sup>®</sup> (dronedarone) Tablets\*
- Priftin® (rifapentine) Tablets
- SOLIQUA® 100/33 (insulin glargine & lixisenatide injection) 100 Units/mL and 33 mcg/mL
- Tenivac<sup>®</sup> (tetanus and diphtheria toxoids adsorbed)
- Thymoglobulin<sup>®</sup> [Anti-thymocyte Globulin (Rabbit)]\*
- Toujeo<sup>®</sup> (insulin glargine injection) 300 units/mL
- Zaltrap<sup>®</sup> (ziv-aflibercept)\*

\*Please see full U.S. prescribing information, including Black Box warning.

Full U.S. prescribing information for all Sanofi Patient Connection supported products can be accessed at <a href="www.visitspconline.com">www.visitspconline.com</a>.

## PATIENT ASSISTANCE CONNECTION ELIGIBILITY REQUIREMENTS

- · An application must be submitted for each patient.
- Patient must be a U.S. citizen or resident and be under the care of a licensed healthcare provider authorized to prescribe, dispense and administer medicine in the U.S. (State License Number is required in Section 3).
- · Patient must have no insurance coverage or not have access to the prescribed product or treatment via their insurance.
- If a patient has Medicare Part D coverage they can be assessed for patient assistance eligibility by meeting these criteria:
  - Not have coverage for a generic equivalent product
  - Have an out-of-pocket (OOP) total drug spend of 5% of their annual income
- If a patient appears to be eligible for Medicaid they may be required to provide documentation of Medicaid denial before being assessed for patient
  assistance eligibility.
- · Patient must meet the following financial criteria:
  - Annual household income of ≤250% of the current Federal Poverty Level\* for all non-Oncology/non-Hematology products
  - Annual household income of ≤500% of the current Federal Poverty Level\* for all Oncology and Hematology products
- If applying for Drug Replacement (Lovenox, Oncology and Hematology products only), a copy of the claim, denial, flow sheet(s) and drug dispensing log
  (with patient name, date of service, product NDC/Lot#, total dosage) must be submitted.
- For Vaccines, patient must be 19 years of age or older (except for IMOVAX RABIES and IMOGAM RABIES HT).

\*To assess current Federal Poverty Level details, visit: http://aspe.hhs.gov.

## **ADDITIONAL INFORMATION**

- · A representative from Sanofi may contact you for follow-up on any adverse event you may report regarding a Sanofi product.
- Sanofi Patient Connection is also pleased to provide you with access to the "SPC Education Center" by calling 855.977.2338 (855.9SPCEDU), Monday through Friday, 9:00 am to 8:00 pm ET. You can speak to a live counselor dedicated to:
  - Providing information about local healthcare reform related resources
  - Directing you to either the federal or state-run Health Insurance Marketplace

## FORM SUBMISSION OPTIONS



Secure Provider Portal www.visitspconline.com



**Fax** 1.888.847.1797



U.S. Mail



